Safer Engineered Bacteria Revolutionize Cancer Therapy
Bio-Engineered Bacteria for Cancer Therapy
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This patented technology leverages engineered Salmonella typhimurium YB1 to target tumors selectively, minimizing damage to normal tissues and enhancing treatment safety. YB1 suppresses tumor growth, inhibits metastasis, and stimulates immune responses, with proven efficacy in breast, liver, and other solid tumors during animal trials. Applications include advanced anti-cancer therapies and drug delivery systems for improved therapeutic outcomes. An upgraded YB1 version equipped with Diphtheria toxin A demonstrated complete tumor suppression and cancer cell death. Patents across the US, China, and Europe protect this groundbreaking approach to cancer treatment.
IP Type or Form Factor: Patent Granted; Process & Method; Material
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
